Hamrita B, Nasr H B, Chahed K, Chouchane L
Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Tunisia.
Gulf J Oncolog. 2011 Jan(9):36-44.
Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The advent of proteomics provides the hope of discovering novel biological markers that can be used for early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast.
Breast cancer is a major health problem and one of the leading causes of death among women worldwide. Its incidence is steadily rising in developing countries. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year(1). Invasive carcinomas represent 70-80% of all breast cancer and among these, infiltrating ductal carcinomas (IDCA) are the most aggressive forms and have a poor prognosis(2). Histopathologically identical breast cancers show a different biological behavior in terms of aggressiveness, progression, and response to therapy. Thus, there is a great need for new breast cancer biomarkers that might help detect this cancer at an earlier stage, to uncover prognostically distinct subclasses, and to provide best individual treatment(2). Currently, the search for specific cancer-related alterations are largely carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Two dimensional gel electrophoresis coupled with mass spectrometry constitute a new proteomics based paradigm for detecting disease in pathology specimens and monitoring disease response to therapy. This review describes these proteomics technologies and their application in the analysis of breast carcinoma.
乳腺癌是女性中诊断出最多的癌症，在美国每年约有40000人死亡。在突尼斯，乳腺癌的发病率约为每年每10万名女性中有19例新发病例。在检测和治疗领域已取得重大进展，但仍有大量乳腺癌发现较晚。蛋白质组学的出现为发现可用于早期检测、预后评估、诊断和治疗的新型生物标志物带来了希望。几种蛋白质组学技术已被用于揭示与乳腺癌相关的分子机制。
乳腺癌是一个主要的健康问题，是全球女性死亡的主要原因之一。其发病率在发展中国家呈稳步上升趋势。在突尼斯，乳腺癌的发病率约为每年每10万名女性中有19例新发病例(1)。浸润性癌占所有乳腺癌的70 - 80%，其中浸润性导管癌(IDCA)是最具侵袭性的类型，预后较差(2)。组织病理学上相同的乳腺癌在侵袭性、进展和对治疗的反应方面表现出不同的生物学行为。因此，迫切需要新的乳腺癌生物标志物，以帮助在更早阶段检测这种癌症，揭示预后不同的亚类，并提供最佳的个体化治疗(2)。目前，在全球范围内寻找与癌症相关的特定改变主要是针对癌组织，以发现能够高灵敏度和特异性地区分疾病状态和无病状态的蛋白质模式。二维凝胶电泳结合质谱分析构成了一种基于蛋白质组学的新范式，用于检测病理标本中的疾病并监测疾病对治疗的反应。本综述描述了这些蛋白质组学技术及其在乳腺癌分析中的应用。
